A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Trial Profile

A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Jul 2017

At a glance

  • Drugs Ixazomib (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms TOURMALINE-MM4
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 07 Jun 2016 Results from this trial and other trial (NCT02181413) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 26 Feb 2016 According to a Takeda Pharmaceuticals media release, the Japanese Ministry of Health, Labour and Welfare has granted Orphan Drug desgination to ixazomib for the treatment of patients with relapsed and/or refractory multiple myeloma.
    • 22 Sep 2015 According to Takeda media release, results will be presented at the upcoming 15th International Myeloma Workshop (IMW 2015).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top